Asessment of Serum Procalcitonin Level in Patients with Chronic Obstructive Pulmonary Disease

Issa, S.A.; Elmahdy, M.A.; ElShimi, O.S.; ElNaggar, M.E.; Behairy, M.M.

doi:10.21608/bjas.2021.214832

	Asessment of Serum Procalcitonin Level in Patients with Chronic Obstructive Pulmonary Disease
Benha Journal of Applied Sciences
Article 40, Volume 6, Issue 6, December 2021, Page 319-324 PDF (836.4 K)
Document Type: Original Research Papers
DOI: 10.21608/bjas.2021.214832
View on SCiNiTO
Authors
S.A. Issa¹; M.A. Elmahdy¹; O.S. ElShimi²; M.E. ElNaggar¹; M.M. Behairy¹
¹Chest Diseases, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
²Clinical and Chemical Pathology, Dept., Faculty of Medicine, Benha Univ., Benha, Egypt
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is currently one of the leading causes of mortality in the globe, according to the World Health Organization. When COPD sufferers have an acute exacerbation, the infection-detecting hormone procalcitonin (PCT) may be administered (AECOPD). The development of COPD is linked to PCT and other viral inflammatory variables. The goal of this research was to determine the PCT level in patients with COPD. Methods: ELISA was used to monitor PCT levels throughout AECOPD and after the patient was stabilised. Study groups differed significantly in PCT results (P-value 0.001). Stable (2220.9 pg/ml) and exacerbation (2679 pg/ml) groups had higher levels, whereas the control group had considerably lower levels (1696.9 pg/ml). Compared to the control group (2220.9 pg/ml), it was considerably greater in the exacerbation group (2679 pg/ml). Conclusion: In patients with stable COPD and AECOPD, PCT has a negative relationship with severity.
Keywords
COPD; AECOPD; Procalcitonin


Statistics Article View: 92 PDF Download: 263